432.89
+1.68(+0.39%)
Currency In USD
| Previous Close | 431.21 |
| Open | 434.6 |
| Day High | 436.44 |
| Day Low | 428 |
| 52-Week High | 443 |
| 52-Week Low | 200.63 |
| Volume | 273,418 |
| Average Volume | 377,932 |
| Market Cap | 9.65B |
| PE | -34.25 |
| EPS | -12.64 |
| Moving Average 50 Days | 347.31 |
| Moving Average 200 Days | 322.06 |
| Change | 1.68 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $5,975.02 as of September 08, 2025 at a share price of $432.89. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $4,245.68 as of September 08, 2025 at a share price of $432.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, Sept. 8, 2025 at 7:45 A
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire Inc.
Aug 19, 2025 8:05 PM GMT
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra reduced fibros
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 11, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.